New targeted pill tested for Hard-to-Treat cancers
NCT ID NCT05732831
Summary
This early-stage study is testing a new oral medication called TNG462, both alone and combined with an existing immunotherapy drug (pembrolizumab), for people with advanced solid tumors that have a specific genetic change called an MTAP deletion. The main goals are to find safe doses and see if the treatment can shrink tumors. The study plans to enroll about 225 adults whose cancer has progressed despite prior standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Brest
RECRUITINGBrest, 29200, France
Contact
-
Carle Cancer Center
RECRUITINGUrbana, Illinois, 61801, United States
Contact
-
Centre Berard Leon
RECRUITINGLyon, 69373, France
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Florida Cancer Specialists & Research Institute
RECRUITINGLake Mary, Florida, 32746, United States
Contact
-
Grand Valley Oncology
RECRUITINGGrand Junction, Colorado, 81505, United States
Contact
-
Henry Ford Cancer Center
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
Hospital HM Nou Delfos
RECRUITINGBarcelona, 08023, Spain
Contact
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
Contact
-
Hospital Universitario Virgen de la Victoria
RECRUITINGMálaga, 29010, Spain
Contact
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, 41013, Spain
Contact
-
Hospital de Sanchinarro
RECRUITINGMadrid, 28050, Spain
Contact
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
-
ICO l'Hospitalet - Hospital Duran i Reynals
RECRUITINGBarcelona, 08908, Spain
Contact
-
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS
RECRUITINGSaint-Herblain, 44805, France
Contact
-
Institute Gustav Roussy
RECRUITINGVillejuif, 94805, France
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02214, United States
Contact
-
Midwestern Regional Medical Center, City of Hope Chicago
RECRUITINGZion, Illinois, 60099, United States
Contact
-
New York University Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
Next Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Sarah Cannon Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
-
Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University Chicago Medicine
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
Vall d'Hebron Barcelona Hospital
RECRUITINGBarcelona, Catalonia, Spain
Contact
Conditions
Explore the condition pages connected to this study.